O MI 28 AND REAL STATES

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

×	Substitute	for form 1449A/PTC)		Complete if Known			
					Application Number	09/580,018	RECEIVED	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	May 26, 2000		
					First Named Inventor	Dale B.Schenk	JU 31 700	
					Art Unit	1647	OOL OI (UUU)	
		(use as many she	ets as	necessary)	Examiner Name	Christopher J. Nichols	TENANT	
abla	Sheet	1	of	4	Attorney Docket Number	15270J-004760US	TECH CENTER 1600/2000	

U.S. PATENT DOCUMENTS								
		Document Number						
Examiner	Cite No.	Number Kind Code ² (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
(3)	360	2003/0073655 A1	04-17-2003	Chain				
	370	2003/0068325 A1	04-10-2003	Wang				
	366	2002/0187157 A1	12-12-2002	Jensen et al.				
	340	2002/0162129 A1	10-31-2002	Lannfelt				
	365	2002/0133001 A1	09-19-2002	Gefter et al.				
	362	2002/0094335 A1	07-18-2002	Chalifour et al.				
	376	2002/0086847	07-04-2002	Chain				
	342	2002/0009445 A1	01-24-2002	Du et al.				
	345	2002/0077288 A1	06-21-2001	Frangione				
	346	5,935,927	. 08-10-1999	Vitek et al.				
	353	5,824,322	10-20-1998	Balasubramanian				
	357	5,776,468 B1	07-07-1998	Hauser et al.				
	373	5,721,130	02-24-1998	Seubert et al.				
7	356	5,622,701	04-22-1997	Berg				
Con	358	5,583,112 B2	12-10-1996	Kensil et al.				

Examiner	111:00	Date	7124104	
Signature	$/ \wedge N (I/a >$	Considered	45101	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Stelement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

O MI 2 8 MM BE

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB contains a valid

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/580,018

Filing Date May 26, 2000 CIT 1 (0) 3

First Named Inventor Dale B.Schenk

Art Unit 1647 LECH CENTER 150 (20)

(use as many sheets as necessary)

Examiner Name

Christopher J. Nichols

Sheet 2 of 4 Attorney Docket Number 15270J-004760US

U.S. PATENT DOCUMENTS							
Examiner	Cite No.	Document Number Number Kind Code ² (# known)	Filing Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS									
Examiner	Cite	For	reign Patent Docur	ment	Publication	Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	Country Code 3	Number⁴	Kind Code ⁶ (# known)	Date MM-DD- YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶	
200	352	. wo	02/34777	A1	05-02-2002				
	351	wo	02/34878	A2	05-02-2002				
	343	EP	1 172 378	A1	01-16-2002				
	344	wo	01/90182	A2	11-29-2001				
J	348	wo	01/77167	A2	10-18-2001				
CRD	341	wo	02/03911	A2	04-07-2001			<u> </u>	

Examiner Signature Date Considered 2/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

2003

1600/2800

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademerk Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ubstitute for form 1449B/PTO

C mplete if Known **Application Number** 09/580,018 **Filing Date** May 26, 2000 **First Named Inventor** Dale B. Schenk Art Unit 1647 TECH CENTER Christopher J. Nichols **Examiner Name**

(use as many sheets as necessary)

15270J-004760US Sheet of 4 Attorney Docket Number

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
مين	372	AKIYAMA et al., "Occurrence of the Diffuse Amyloid β-Protein (Aβ) Deposits With Numerous Aβ-Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," Glia, 25:324-331 (1999).	_
	363	DODART, "Immunotherapy for Alzhelmer's disease: will vaccination work?". <u>Trends in Molecular Medicine</u> , 9(3):85-87 (2003).	_
	364	FURLAN et al., "Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice," Brain, 126:285-291 (2003).	
	374	JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," <u>Alzheimer Disease and Associated Disorders</u> , 9(1):47-51, Raven Press, Ltd., New York (1995).	
	371	JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the β-Amylold Peptide (1-43) in Transfected 293 Cells, Biochemical and Biophysical Research Communications, 220:710-718 (1996).	_
	347	JORBECK et al., "Artificial Salmonella Vaccines: Salmonella typhimurium O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," Infection and Immunity, May:497-502 (1981).	
	367	MONSONEGO et al., "Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," <u>PNAS</u> , 98(18):10273-10278 (2001).	_
	359	MUNCH et al., "Potentional neurotoxic inflammatory response to Aβ vaccination in humans," (2002) <u>J. Neural Transm.</u> , 109:1081-1087.	
	355	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York.	_
	354	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany.	_
A	368	SIPE, "Amyloidosis," <u>Annu, Rev. Biochem.</u> , 61:947-975 (1992).	_
600	369	SPOONER et al., "The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol," <u>Vaccine</u> , 21:290-297 (2002).	

Examiner Date Considered Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3320092 v1

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

O IN 18 MILES

PTO/SB/08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031

600/2000

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

Application Number 09/580,018 RECF

Filing Dat May 26, 2000

First Named Inventor Dale B. Schenk

Art Unit 1647

(use as many sheets as necessary)

Sheet 4 of 4

Substitute for form 1449B/PTO

leets as necessary)

Examiner Name

Christopher J. Nichols

TECH CENTER

Attorney Docket Number

15270J-004760US

361 SU et al., "Intravascular infusions of soluble β-amyloid compromise the blood-brain barrier, activate CNS Glial cells and Induce peripheral hemorrhage," Brain Research, 818:105-107 (1999).

TSUZUKI et al., "Amyloid β protein in rat soleus in choroquine-Induced myopthy using end-specific antibodies for Aβ40 and Aβ42: immunohistochemical evidence for amyloid β protein," Neuroscience Letters, 2002:77-80 (1995).

	· · · · ·		
Examiner Signature	CMID	Date Considered	2/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page of 1

Complete if Known					
Application Number	09/580,018	_			
Filing Date	May 26, 2000	_			
First Named Inventor	Schenk, Dale B.	_			
Art Unit	1647				
Examiner Name	Christopher Nichols				
Attorney Docket Number	15270J-004760US	ブ			

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2					
600	349	CHECK, "Battle of the Mind," Nature, 422:370-372 (March 2003).						
CON	350	Nicoll et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report," Nature Medicine, 9(4):448-452 (April 2003).						

RECEIVED TECH CENTER 1600/2900

	T		
Examiner Signature	(Mie)	Date Considered	2/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include dopy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is Tequired by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 130 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete including cathedra preparing and submitted application form to the USPTO. Time will keep depending upon the minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Kn wn

09/580,018

May 26, 2000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Application Number

Filing Date

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Page

First Named Inventor Schenk, Dale B., et. al. 1647 Art Unit

(use as many sheets as necessary) Christopher J. Nichols Examiner Name 5 15270J-004760US Attorney Docket Number

U.S. PATENT DOCUMENTS Document Number Publication Date Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Relevant Number Kind Code¹ (if known) Examine Figures Appear لتوي 360 2003/0073655 A1 04-17-2003 Chain 370 2003/0068325 A1 04-10-2003 Wang Ghanbari et al. 378 2002/0197258 A1 12-26-2003 366 2002/0187157 A1 12-12-2002 Jensen et al. 377 2002/0168377 A1 11-14-2002 Schaetzl 10-31-2002 Lannfelt 340 2002/0162129 A1 10-**-2002 Wu 395 2002/0160394 A1 379 2002/0132268 A1 09-19-2002 Chang et al 09-19-2002 Gefter et al. 365 2002/0133001 A1 362 2002/0094335 A1 07-18-2002 Chalifour et al. 376 2002/0086847 07-04-2002 Chain 342 2002/0009445 A1 01-24-2002 Du et al. 2001/0021769 A1 381 09-13-2001 Prusiner 345 2002/0077288 A1 06-21-2001 Frangione 346 5,935,927 08-10-1999 Vitek et al. 382 5,846,533 12-08-1998 Prusiner 353 5,824,322 10-20-1998 Balasubramanlan 357 5,776,468 B1 07-07-1998 Hauser et al. 380 5,750,361 05-12-1998 Prusiner et al. 02-24-1998 Seubert et al. 373 5,721,130 356 5,622,701 04-22-1997 Berg ∞ 358 5,583,112 B2 12-10-1996 Kensil et al.

Examiner Date 2/24/2004 Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

and not considered. Include copy of his form with next communication to applicant.

Applicant's unique citation designation number (optional). Citation Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

AUG 2 0 2003 PRADEN A TRADEN

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

C mplete if Known

15270J-004760US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Attorney Docket Number

Application Number INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date May 26, 2000 First Named Inventor Schenk, Dale B., et. al. Art Unit 1647 Christopher J. Nichols **Examiner Name**

09/580,018

(use as many sheets as necessary) Page 5

Substitute for form 1449/PTO

FOREIGN PATENT DOCUMENTS								
Evaminas	2:-	For	eign Patent Documer	nt		Name of Batastan or	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code ³ Number ⁴		Code ^s (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T°
630	343	EP	1 172 378	A1	01-16-2002			-0
	351	wo	02/34878	A2	05-02-2002			0
	352	wo	02/34777	A1	05-02-2002			0
	341	wo	02/03911	A2	04-07-2001			0
	344	wo	01/90182	A2	11-29-2001			- 0
A.	348	wo	01/77167	Ą2	10-18-2001			0
CDS	383	wo	97/10505	A1	03-20-1997			0
1		l .						1 🗆

PECEIVEI PECH CENTER 1600/2900

Examiner	/ / _	Date	//
Signature	() 1/1/5	Considered	712412004
<u> </u>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation (esignation number (optional). 2 Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of Observation 1 Particle 1 Part under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file cand by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

AUG 2 0 2003

RADEN'S

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/580,018 **Filing Date** May 26, 2000 First Named Inventor Schenk, Dale B., et. al. Art Unit 1647 **Examiner Name** Christopher J. Nichols

				Art Unit	1647	_ [
(use as many sheets as necessary)		Examiner Name	Christopher J. Nichols				
Page		3 of	5	Attorney Docket Number	15270J-004760US	フィ	
			····			44	
		*****	NON PATE	NT LITERATURE DOCUME	NTS CA		
Examiner Initials *	Cite No.1	Include na item (b	ook, magazine, jou	CAPITAL LETTERS), title of the mal, serial, symposium, catalog, s), publisher, city and/or country or country	article (when appropriate), title of the etc.), date, page(s), volume-issue where published.		
070	391	AGUZZI et	al., "Prion research:	the next frontiers," Nature, 389:7	95-798 (1997).		
	393	AKIYAMA e	t al., "Inflammation	and Alzheimer's disease," <u>Neuro</u>	biology of Aging, 21:383-421 (2000).		
	372				β) Deposits With Numerous Aβ- thelmer's Disease," <u>Glia,</u> 25:324-331		
	349 CHECK, "Battle of the Mind," Nature,			ature, 422:370-372 (March 2003)	-		
	390 DIOMEDE et al., "Activation effect Biochem. J., 320:53-570 (1996).			ects of a prion protein fragment (F	is of a prion protein fragment [PrP-(106-126)] on human leucocytes,"		
	363	DODART, "I Medicine, 9	mmunotherapy for (3):85-87 (2003).	Alzheimer's disease: will vaccinat	ion work?" <u>Trends in Molecular</u>		
	386	FRATUTSC 8366 (1991)	HY et al., "Effects o	f injected Alzheimer β-amyloid co	res in rat brain," <u>PNAS</u> , 88:8362-	_	
	364	L .	al., "Vaccination wit ce," <u>Brain,</u> 126:285-	h amyloid-β peptide induces auto 291 (2003).	immune encephalomyelitis in	_	
	388	GOLDFARB (1995).	et al., "The Transm	nissible Spongiform Encephalopa	thles," <u>Ann. Rev. Med.,</u> 46:57-65		
	397	GOLDSTEIN and in amylo	IS et al., "Goldstein pidogenic mutants,"	s et al., Éxposure of cryptic epito _l PNAS, 96:3108-3113 (1999).	pes on transthyretin only in amypoid	-	
	374	JAKES et al. Alzheimer D	, "Characterisation isease and Associa	of an Antibody Relevant to the Noted Disorders, 9(1):47-51, Raven	europathology of Alzheimer Disease," Press, Ltd., New York (1995).		
9	371			d Cytoplasmic Localization of the nical and Biophysical Research C	β-Amyloid Peptide (1-43) in communications, 220:710-718 (1996).		

Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 including complete including control in the complete including control in the control of the con minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. AUG 2 0 2000 S

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 4 of 5

	Complete if Known	
Application Number	09/580,018	١,
Filing Date	May 26, 2000	
First Named Inventor	Schenk, Dale B., et. al.	C.
Art Unit	1647	
Examiner Name	Christopher J. Nichols	6. 5
Attorney Docket Number	15270J-004760US	(10))
		300
ERATURE DOCUMENT	rs	Co.
	rticle (when appropriate), title of the	U

		NON PATENT LITERATURE DOCUMENTS	,			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
690	347	JORBECK et al., "Artificial Salmonella Vaccines: Salmonella typhimurium O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," Infection and Immunity, May:497-502 (1981).				
	389	KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," <u>J. Neurol.</u> , 249:1567-1582 (2002).				
	367	MONSONEGO et at., "Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," PNAS, 98(18):10273-10278 (2001).				
	359	MUNCH et al., "Potentional neurotoxic inflammatory response to Aβ vaccination in humans," (2002) <u>J.</u> Neural Transm., 109:1081-1087.				
	355	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York.	_			
	354	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany.				
	350	NICOLL et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report," Nature Medicine, 9(4):448-452 (April 2003).				
	398	PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidiotic polyneuropathy, " <u>J. Mol. Med.</u> , 7:703-707 (2001).	_			
	394	PRUSINER et al., "Abilation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," PNAS, 90:10608-10612 (1993).				
V	396	SIGURDSSON et al., "Anti-priori antibodies for prophylaxis following prion exposure in mice," Neurosciences Letters, 336:185-187 (2003).				
EN	384	SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," American Journal of Pathology, 161:13-17 (2002).				

Examiner Signature	Miss	Date Considered	2/24/04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Page	5	of	5

				PTO/SB/08B (04-03)	
			App. U.S. Palent and Trade	roved for use through 04/30/2003. OMB 0651-0031 mark Office: U.S. DEPARTMENT OF COMMERCE	
Under the Pape	rwork Reduction	Act of 1995, no persons	are required to respond to a collection of	information unless it contains a valid OMB control number	
for form 1449/PTO			C mpl te if Kn wn		
RMATION DISCLOSURE			Applicati n Number	09/580,018	
MATIO	A DISC	LUSUKE	Filing Dat	May 26, 2000	
		PLICANT	First Nam d Invent r	Schenk, Dale B., et. al.	%
MENT	BY APF		First Nam d Invent r Art Unit		Ò
	BY APF			Schenk, Dale B., et. al. 1647 Christopher J. Nichele	Ò
MENTI	BY APF		Art Unit	Schenk, Dale B., et. al.	ò

····		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	400	SIGURDSSON et al., "A safer vaccine for Alzhelmer's disease?," Neurobiology of Aging, 23:1001-1008 (2002).	_			
	368	SIPE, "Amyloidosis," <u>Annu. Rev. Biochem.</u> , 61:947-975 (1992).	-			
	369	SPOONER et al., "The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol," <u>Vaccine</u> , 21:290-297 (2002).	-			
	361	SU et al., "Intravascular infusions of soluble β-amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," <u>Brain Research</u> , 818:105-107 (1999).	_			
	392	TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival In Experimental Prion Disease in Mice," <u>Journal of Neuroscience Research</u> , 71:286-290 (2003).	-			
	399	TAN et al., "Amyloidosis," Histopathology, 25:403-414 (1994).	-			
	375	TSUZUKI et al., "Amyloid β protein in rat soleus in choroquine-induced myopthy using end-specific antibodies for A β 40 and A β 42: immunohistochemical evidence for amyloid β protein," Neuroscience Letters, 2002:77-80 (1995).	_			
Ψ	387	WELDON et al., "Neurotoxicity of Aß Peptide: Confocal Imaging of Cellular Changes Induced by – Amyloid in Rat CNS In Vivo," Society for Neuroscicence Abstracts, 22(Part 1) (1996).	_			
W	385	WISNIEWSKI et al., "Therapeutics In Alzheimer's and Prion Diseases," <u>Biochemical Society</u> <u>Transactions</u> , 30(4):-574-587 (2002).	F			

Examiner		1. ()	Date	
	· / /		Date	
Signature		/// n	Considered	1 /// 9 /()7
		(I)	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw fine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office. U.S. Department of Commerce. Washington. DC 20231. DO NOT SEND FEES OR the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.